Kamada Ltd (KMDA) 4.15 $KMDA
Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2014 - 38 Companies & 67 Drug Profiles
M2 - Thu Nov 06, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/rdllgl/graft_versus_host) has announced the addition of the "Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Graft Versus Host Disease (GVHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Graft Versus Host Disease (GVHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - F. Hoffmann-La Roche Ltd. - Biogen Idec Inc. - Athersys, Inc. - Seattle Genetics, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Idera Pharmaceuticals, Inc. - Mesoblast Limited - Jazz Pharmaceuticals plc - Alexion Pharmaceuticals, Inc. - Soligenix, Inc. - NeoStem, Inc. - Pharmacyclics, Inc. - Pluristem Therapeutics Inc. - MediPost Co., Ltd. - Kamada Ltd. - R-Tech Ueno, Ltd. - Omni Bio Pharmaceutical Inc. - Alder Biopharmaceuticals Inc. - MSM Protein Technologies, Inc. For more information visit http://www.researchandmarkets.com/research/rd...ersus_host
BIIB: 320.75 (-2.72), PCYC: 133.49 (-3.63), PSTI: 2.66 (-0.08), NBS: 4.85 (unch), ALDR: 16.57 (-0.25), IDRA: 2.43 (-0.06), SGEN: 36.05 (+1.20), JAZZ: 170.80 (-1.57), ALXN: 193.81 (+0.67), KMDA: 4.15 (+0.15), ATHX: 1.53 (-0.04), NVS: 91.76 (-0.27)
FDA Grants Kamada Orphan Drug Designation for the Treatment of Graft versus Host Disease
Business Wire - Wed Oct 29, 7:36AM CDT
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that the U.S. Food and Drug Administration's (FDA) Office of Orphan Products Development has granted orphan drug designation for Glassia(R), the Company's proprietary human Alpha-1 Antitrypsin (AAT), to treat Graft-versus-host-disease (GVHD). Orphan drug designation carries multiple benefits, including the availability of grant money, certain tax credits and seven years of market exclusivity, as well as the possibility of an expedited regulatory process.
KMDA: 4.15 (+0.15)
Kamada Announces Study in Support of Alpha-1 Antitrypsin for the Treatment of Type-1 Diabetes Published in the Journal of Diabetes Science and Technology
Business Wire - Tue Oct 21, 6:00AM CDT
Kamada Ltd. (Nasdaq: KMDA) (TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that a comprehensive review of the data available in the literature in support of the mechanism of action of Alpha-1 Antitrypsin (AAT) for the treatment of Type-1 Diabetes, was published in the August 2014 edition of the peer-reviewed, Journal of Diabetes Science and Technology. The online version of the review article, titled, "Mechanistic Evidence in Support of Alpha-1 Antitrypsin as a Therapeutic Approach for Type-1 Diabetes" can be accessed at: http://dst.sagepub.com/content/early/2014/08/...6814547096.
KMDA: 4.15 (+0.15)
Kamada Announces Second Extension of Strategic Agreement with Baxter
Business Wire - Mon Sep 29, 5:30AM CDT
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announced today the second extension to supply Glassia(R) to Baxter in its strategic agreement with the biopharmaceutical business of Baxter International Inc. Through the extended agreement, Kamada secured $26 million in additional revenues of Glassia, the Company's proprietary, ready-to-infuse liquid alpha-1 antitrypsin (AAT) treatment that is indicated as a chronic augmentation and maintenance therapy in adults with clinically evident emphysema due to severe congenital AAT deficiency, through 2017. As a result, Kamada expects that total revenue generated through this agreement from October 2010 through end of 2017 will increase to a minimum of $191 million compared with a minimum of $110 million contained in the original agreement executed in 2010 and a minimum of $165 million contained in the May 2013 extension.
BAX: 70.61 (-0.99), KMDA: 4.15 (+0.15)
Market Maker Surveillance Report. GT, KERX, CPE, AXAS, MNGGF, KMDA, Losing Stocks With Lowest Price Friction For Monday, September 8th 2014
M2 - Tue Sep 09, 3:28AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 4710 companies with "abnormal" market making, 2110 companies with positive Friction Factors and 2786 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Monday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. The Goodyear Tire & Rubber Co (NYSE:GT), Keryx Biopharmaceuticals Inc (NASDAQ:KERX), Callon Petroleum Co (NYSE:CPE), Abraxas Petroleum Corp (NASDAQ:AXAS), (OTC:MNGGF), (NASDAQ:KMDA). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
GT: 25.15 (unch), CPE: 6.64 (+0.54), KMDA: 4.15 (+0.15), AXAS: 4.28 (+0.21), KERX: 16.73 (-0.47)
Silver Spring Networks Starts The Week Strong
at The Street - Mon Sep 08, 12:30PM CDT
Silver Spring Networks Inc (NYSE:SSNI), Essent Group Ltd (NYSE:ESNT) and LipoScience Inc (NASDAQ:LPDX) are today's top-gaining billionaire stock picks midday. Having a tough start to the week are ...
CXO: 117.88 (+5.68), LPDX: 5.23 (+0.01), KMDA: 4.15 (+0.15), ESNT: 24.08 (+0.06), SSNI: 7.73 (+0.09), KERX: 16.73 (-0.47)
Market Maker Surveillance Report. MTRX, MIND, VII, ZQK, SGOC, KMDA, Losing Stocks With Lowest Price Friction For Thursday, September 4th 2014
M2 - Fri Sep 05, 3:15AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 4751 companies with "abnormal" market making, 1909 companies with positive Friction Factors and 3133 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Thursday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Matrix Service Co (NASDAQ:MTRX), Mitcham Industries Inc (NASDAQ:MIND), Vicon Industries Inc (NYSE:VII), QUIKSILVER, INC. (NYSE:ZQK), SOLOMON GOLD CORP (NASDAQ:SGOC), (NASDAQ:KMDA). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
MTRX: 22.99 (+0.50), SGOC: 1.63 (+0.10), ZQK: 1.97 (-0.06), KMDA: 4.15 (+0.15), VII: 1.64 (+0.01), MIND: 9.60 (-0.15)
Kamada Plunges Following Missed Marks In Trial
at The Street - Thu Sep 04, 11:52AM CDT
UTi Worldwide Inc. (NASDAQ:UTIW), Flexion Therapeutics Inc (NASDAQ:FLXN) and PVH Corp (NYSE
VH) are today's top-gaining billionaire stock picks midday. On the losing end are Kamada Ltd (NASDAQ:KM...
UTIW: 11.18 (+0.06), FLXN: 18.94 (-0.09), CNDO: 1.74 (+0.13), KMDA: 4.15 (+0.15), CIEN: 16.62 (+0.23), PVH: 118.19 (+0.78)
Kamada Reports Final Results from Phase 2/3 Clinical Trial of Inhaled Alpha-1 Antitrypsin to Treat Alpha-1 Antitrypsin Deficiency
Business Wire - Thu Sep 04, 6:00AM CDT
--First AAT deficiency treatment to show impact on lung function
KMDA: 4.15 (+0.15)
Kamada to Announce Final Results from Phase 2/3 Clinical Trial of Inhaled AAT to Treat Alpha-1 Antitrypsin Deficiency on September 4, 2014
Business Wire - Wed Sep 03, 3:29PM CDT
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, will announce the final results from its European Phase 2/3 clinical trial of its proprietary inhaled alpha-1 antitrypsin (AAT) to treat alpha-1 antitrypsin deficiency (AATD) on Thursday, September 4, 2014 at approximately 7:00 a.m. Eastern time.
KMDA: 4.15 (+0.15)
Kamada Reports Second Quarter Financial Results
Business Wire - Thu Aug 14, 7:02AM CDT
--Conference Call Begins Today at 8:30 a.m. Eastern Time
KMDA: 4.15 (+0.15)
Kamada to Host Second Quarter Financial Results Conference Call on Thursday, August 14, 2014
Business Wire - Wed Aug 06, 6:00AM CDT
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that it will release its financial results for the three and six months ended June 30, 2014 prior to the market open on Thursday, August 14, 2014.
KMDA: 4.15 (+0.15)
Should You Get Rid of Kamada (KMDA) Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jul 11, 7:34AM CDT
Kamada one such stock that can be considered to drop as it has witnessed a significant price decline and has seen negative earnings estimate
CRIS: 1.30 (+0.01), BIIB: 320.75 (-2.72), KMDA: 4.15 (+0.15)
Alpha- Antitrypsin Deficiency - Pipeline Review, H1 2014
M2 - Thu Jul 03, 5:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4lpdgx/alpha) has announced the addition of the "Alpha- Antitrypsin Deficiency - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Alpha- Antitrypsin Deficiency, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alpha- Antitrypsin Deficiency and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Alpha- Antitrypsin Deficiency - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Alpha- Antitrypsin Deficiency pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Sangamo BioSciences, Inc. - Grifols, S.A. - rEVO Biologics - International Stem Cell Corporation - Kamada Ltd. - Dicerna Pharmaceuticals, Inc. - Cevec Pharmaceuticals GmbH - Applied Genetic Technologies Corporation - Intrexon Corporation - Polyphor Ltd. - iBio, Inc. - OrphageniX, Inc. - Carolus Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/4lpdgx/alpha
DRNA: 9.11 (+0.97), SGMO: 11.32 (-0.32), XON: 21.15 (+0.21), KMDA: 4.15 (+0.15), IBIO: 1.16 (+0.07)
Emphysema - Pipeline Review, H1 2014
M2 - Fri Jun 27, 5:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6x5xq8/emphysema) has announced the addition of the "Emphysema - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Emphysema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Emphysema and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Emphysema - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Emphysema pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Protalix BioTherapeutics, Inc. - Kamada Ltd. - Intrexon Corporation - Medestea Research & Production S.p.A. For more information visit http://www.researchandmarkets.com/research/6x5xq8/emphysema
XON: 21.15 (+0.21), KMDA: 4.15 (+0.15)
Kamada Announces Initiation of a Phase 2 U.S. Clinical Trial of Inhaled AAT to Treat Alpha-1 Antitrypsin Deficiency
Business Wire - Mon Mar 24, 6:00AM CDT
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces the initiation of a new Phase 2 U.S. clinical trial of its proprietary inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD, or Inherited Emphysema).
KMDA: 4.15 (+0.15)
Outbrain Appoints Ziv Kop As COO
PR Newswire - Fri Mar 21, 12:30PM CDT
Outbrain, the leading content discovery platform, today announced that Ziv Kop, founding member of Outbrain's Board of Directors and former Managing Partner at GlenRock Israel, has joined the company as Chief Operating Officer.
EVGN: 10.50 (-0.01), KMDA: 4.15 (+0.15)
Kamada to Report Top-Line Data from Phase 2/3 Clinical Trial of Inhaled AAT to Treat Alpha-1 Antitrypsin Deficiency by Late April or Early May
Business Wire - Fri Mar 21, 6:00AM CDT
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that it expects to report top-line data from the pivotal Phase 2/3 clinical trial in Europe and Canada of the Company's proprietary inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD or Inherited Emphysema) by the end of April or the beginning of May. Previously the Company expected to report the data by the end of the first quarter of 2014. Kamada plans to issue a news release in advance of the announcement of top-line data with the specific date and time of the data release.
KMDA: 4.15 (+0.15)
Why You Need to Pay Attention to Kamada (KMDA) Stock? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 8:00AM CST
Kamada has seen its Zacks Rank surge over the past four weeks, moving from Sell territory to its current position as a Buy. A key reason for this move has been the positive trend in the earnings estimate revisions picture.
EBS: 23.95 (+1.46), ALXN: 193.81 (+0.67), KMDA: 4.15 (+0.15), ALKS: 51.00 (-0.03)
Kamada Initiates Phase 2/3 Clinical Trial of Glassia to Treat Newly Diagnosed Pediatric Patients with Type 1 Diabetes
Business Wire - Wed Mar 05, 6:00AM CST
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces the initiation of a Phase 2/3 clinical trial of Glassia(R), the Company's proprietary human Alpha-1 Antitrypsin (AAT), to treat newly diagnosed pediatric patients with type 1 diabetes (T1D). In T1D, autoimmune attacks occur on pancreatic beta cells that secrete insulin, thereby compromising insulin level and glycemic control. Over time there is progressive deterioration of self-insulin secretion, poor capability to control glucose levels, and eventually, full external insulin dependence.
KMDA: 4.15 (+0.15)
Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2014 - 38 Companies & 67 Drug Profiles
M2 - Thu Nov 06, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/rdllgl/graft_versus_host) has announced the addition of the "Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Graft Versus Host Disease (GVHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Graft Versus Host Disease (GVHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - F. Hoffmann-La Roche Ltd. - Biogen Idec Inc. - Athersys, Inc. - Seattle Genetics, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Idera Pharmaceuticals, Inc. - Mesoblast Limited - Jazz Pharmaceuticals plc - Alexion Pharmaceuticals, Inc. - Soligenix, Inc. - NeoStem, Inc. - Pharmacyclics, Inc. - Pluristem Therapeutics Inc. - MediPost Co., Ltd. - Kamada Ltd. - R-Tech Ueno, Ltd. - Omni Bio Pharmaceutical Inc. - Alder Biopharmaceuticals Inc. - MSM Protein Technologies, Inc. For more information visit http://www.researchandmarkets.com/research/rd...ersus_host
BIIB: 320.75 (-2.72), PCYC: 133.49 (-3.63), PSTI: 2.66 (-0.08), NBS: 4.85 (unch), ALDR: 16.57 (-0.25), IDRA: 2.43 (-0.06), SGEN: 36.05 (+1.20), JAZZ: 170.80 (-1.57), ALXN: 193.81 (+0.67), KMDA: 4.15 (+0.15), ATHX: 1.53 (-0.04), NVS: 91.76 (-0.27)
FDA Grants Kamada Orphan Drug Designation for the Treatment of Graft versus Host Disease
Business Wire - Wed Oct 29, 7:36AM CDT
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that the U.S. Food and Drug Administration's (FDA) Office of Orphan Products Development has granted orphan drug designation for Glassia(R), the Company's proprietary human Alpha-1 Antitrypsin (AAT), to treat Graft-versus-host-disease (GVHD). Orphan drug designation carries multiple benefits, including the availability of grant money, certain tax credits and seven years of market exclusivity, as well as the possibility of an expedited regulatory process.
KMDA: 4.15 (+0.15)
Kamada Announces Study in Support of Alpha-1 Antitrypsin for the Treatment of Type-1 Diabetes Published in the Journal of Diabetes Science and Technology
Business Wire - Tue Oct 21, 6:00AM CDT
Kamada Ltd. (Nasdaq: KMDA) (TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that a comprehensive review of the data available in the literature in support of the mechanism of action of Alpha-1 Antitrypsin (AAT) for the treatment of Type-1 Diabetes, was published in the August 2014 edition of the peer-reviewed, Journal of Diabetes Science and Technology. The online version of the review article, titled, "Mechanistic Evidence in Support of Alpha-1 Antitrypsin as a Therapeutic Approach for Type-1 Diabetes" can be accessed at: http://dst.sagepub.com/content/early/2014/08/...6814547096.
KMDA: 4.15 (+0.15)
Kamada Announces Second Extension of Strategic Agreement with Baxter
Business Wire - Mon Sep 29, 5:30AM CDT
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announced today the second extension to supply Glassia(R) to Baxter in its strategic agreement with the biopharmaceutical business of Baxter International Inc. Through the extended agreement, Kamada secured $26 million in additional revenues of Glassia, the Company's proprietary, ready-to-infuse liquid alpha-1 antitrypsin (AAT) treatment that is indicated as a chronic augmentation and maintenance therapy in adults with clinically evident emphysema due to severe congenital AAT deficiency, through 2017. As a result, Kamada expects that total revenue generated through this agreement from October 2010 through end of 2017 will increase to a minimum of $191 million compared with a minimum of $110 million contained in the original agreement executed in 2010 and a minimum of $165 million contained in the May 2013 extension.
BAX: 70.61 (-0.99), KMDA: 4.15 (+0.15)
Market Maker Surveillance Report. GT, KERX, CPE, AXAS, MNGGF, KMDA, Losing Stocks With Lowest Price Friction For Monday, September 8th 2014
M2 - Tue Sep 09, 3:28AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 4710 companies with "abnormal" market making, 2110 companies with positive Friction Factors and 2786 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Monday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. The Goodyear Tire & Rubber Co (NYSE:GT), Keryx Biopharmaceuticals Inc (NASDAQ:KERX), Callon Petroleum Co (NYSE:CPE), Abraxas Petroleum Corp (NASDAQ:AXAS), (OTC:MNGGF), (NASDAQ:KMDA). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
GT: 25.15 (unch), CPE: 6.64 (+0.54), KMDA: 4.15 (+0.15), AXAS: 4.28 (+0.21), KERX: 16.73 (-0.47)
Silver Spring Networks Starts The Week Strong
at The Street - Mon Sep 08, 12:30PM CDT
Silver Spring Networks Inc (NYSE:SSNI), Essent Group Ltd (NYSE:ESNT) and LipoScience Inc (NASDAQ:LPDX) are today's top-gaining billionaire stock picks midday. Having a tough start to the week are ...
CXO: 117.88 (+5.68), LPDX: 5.23 (+0.01), KMDA: 4.15 (+0.15), ESNT: 24.08 (+0.06), SSNI: 7.73 (+0.09), KERX: 16.73 (-0.47)
Market Maker Surveillance Report. MTRX, MIND, VII, ZQK, SGOC, KMDA, Losing Stocks With Lowest Price Friction For Thursday, September 4th 2014
M2 - Fri Sep 05, 3:15AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 4751 companies with "abnormal" market making, 1909 companies with positive Friction Factors and 3133 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Thursday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Matrix Service Co (NASDAQ:MTRX), Mitcham Industries Inc (NASDAQ:MIND), Vicon Industries Inc (NYSE:VII), QUIKSILVER, INC. (NYSE:ZQK), SOLOMON GOLD CORP (NASDAQ:SGOC), (NASDAQ:KMDA). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
MTRX: 22.99 (+0.50), SGOC: 1.63 (+0.10), ZQK: 1.97 (-0.06), KMDA: 4.15 (+0.15), VII: 1.64 (+0.01), MIND: 9.60 (-0.15)
Kamada Plunges Following Missed Marks In Trial
at The Street - Thu Sep 04, 11:52AM CDT
UTi Worldwide Inc. (NASDAQ:UTIW), Flexion Therapeutics Inc (NASDAQ:FLXN) and PVH Corp (NYSE
VH) are today's top-gaining billionaire stock picks midday. On the losing end are Kamada Ltd (NASDAQ:KM... UTIW: 11.18 (+0.06), FLXN: 18.94 (-0.09), CNDO: 1.74 (+0.13), KMDA: 4.15 (+0.15), CIEN: 16.62 (+0.23), PVH: 118.19 (+0.78)
Kamada Reports Final Results from Phase 2/3 Clinical Trial of Inhaled Alpha-1 Antitrypsin to Treat Alpha-1 Antitrypsin Deficiency
Business Wire - Thu Sep 04, 6:00AM CDT
--First AAT deficiency treatment to show impact on lung function
KMDA: 4.15 (+0.15)
Kamada to Announce Final Results from Phase 2/3 Clinical Trial of Inhaled AAT to Treat Alpha-1 Antitrypsin Deficiency on September 4, 2014
Business Wire - Wed Sep 03, 3:29PM CDT
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, will announce the final results from its European Phase 2/3 clinical trial of its proprietary inhaled alpha-1 antitrypsin (AAT) to treat alpha-1 antitrypsin deficiency (AATD) on Thursday, September 4, 2014 at approximately 7:00 a.m. Eastern time.
KMDA: 4.15 (+0.15)
Kamada Reports Second Quarter Financial Results
Business Wire - Thu Aug 14, 7:02AM CDT
--Conference Call Begins Today at 8:30 a.m. Eastern Time
KMDA: 4.15 (+0.15)
Kamada to Host Second Quarter Financial Results Conference Call on Thursday, August 14, 2014
Business Wire - Wed Aug 06, 6:00AM CDT
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that it will release its financial results for the three and six months ended June 30, 2014 prior to the market open on Thursday, August 14, 2014.
KMDA: 4.15 (+0.15)
Should You Get Rid of Kamada (KMDA) Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jul 11, 7:34AM CDT
Kamada one such stock that can be considered to drop as it has witnessed a significant price decline and has seen negative earnings estimate
CRIS: 1.30 (+0.01), BIIB: 320.75 (-2.72), KMDA: 4.15 (+0.15)
Alpha- Antitrypsin Deficiency - Pipeline Review, H1 2014
M2 - Thu Jul 03, 5:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4lpdgx/alpha) has announced the addition of the "Alpha- Antitrypsin Deficiency - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Alpha- Antitrypsin Deficiency, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alpha- Antitrypsin Deficiency and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Alpha- Antitrypsin Deficiency - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Alpha- Antitrypsin Deficiency pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Sangamo BioSciences, Inc. - Grifols, S.A. - rEVO Biologics - International Stem Cell Corporation - Kamada Ltd. - Dicerna Pharmaceuticals, Inc. - Cevec Pharmaceuticals GmbH - Applied Genetic Technologies Corporation - Intrexon Corporation - Polyphor Ltd. - iBio, Inc. - OrphageniX, Inc. - Carolus Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/4lpdgx/alpha
DRNA: 9.11 (+0.97), SGMO: 11.32 (-0.32), XON: 21.15 (+0.21), KMDA: 4.15 (+0.15), IBIO: 1.16 (+0.07)
Emphysema - Pipeline Review, H1 2014
M2 - Fri Jun 27, 5:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6x5xq8/emphysema) has announced the addition of the "Emphysema - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Emphysema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Emphysema and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Emphysema - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Emphysema pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Protalix BioTherapeutics, Inc. - Kamada Ltd. - Intrexon Corporation - Medestea Research & Production S.p.A. For more information visit http://www.researchandmarkets.com/research/6x5xq8/emphysema
XON: 21.15 (+0.21), KMDA: 4.15 (+0.15)
Kamada Announces Initiation of a Phase 2 U.S. Clinical Trial of Inhaled AAT to Treat Alpha-1 Antitrypsin Deficiency
Business Wire - Mon Mar 24, 6:00AM CDT
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces the initiation of a new Phase 2 U.S. clinical trial of its proprietary inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD, or Inherited Emphysema).
KMDA: 4.15 (+0.15)
Outbrain Appoints Ziv Kop As COO
PR Newswire - Fri Mar 21, 12:30PM CDT
Outbrain, the leading content discovery platform, today announced that Ziv Kop, founding member of Outbrain's Board of Directors and former Managing Partner at GlenRock Israel, has joined the company as Chief Operating Officer.
EVGN: 10.50 (-0.01), KMDA: 4.15 (+0.15)
Kamada to Report Top-Line Data from Phase 2/3 Clinical Trial of Inhaled AAT to Treat Alpha-1 Antitrypsin Deficiency by Late April or Early May
Business Wire - Fri Mar 21, 6:00AM CDT
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that it expects to report top-line data from the pivotal Phase 2/3 clinical trial in Europe and Canada of the Company's proprietary inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD or Inherited Emphysema) by the end of April or the beginning of May. Previously the Company expected to report the data by the end of the first quarter of 2014. Kamada plans to issue a news release in advance of the announcement of top-line data with the specific date and time of the data release.
KMDA: 4.15 (+0.15)
Why You Need to Pay Attention to Kamada (KMDA) Stock? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 8:00AM CST
Kamada has seen its Zacks Rank surge over the past four weeks, moving from Sell territory to its current position as a Buy. A key reason for this move has been the positive trend in the earnings estimate revisions picture.
EBS: 23.95 (+1.46), ALXN: 193.81 (+0.67), KMDA: 4.15 (+0.15), ALKS: 51.00 (-0.03)
Kamada Initiates Phase 2/3 Clinical Trial of Glassia to Treat Newly Diagnosed Pediatric Patients with Type 1 Diabetes
Business Wire - Wed Mar 05, 6:00AM CST
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces the initiation of a Phase 2/3 clinical trial of Glassia(R), the Company's proprietary human Alpha-1 Antitrypsin (AAT), to treat newly diagnosed pediatric patients with type 1 diabetes (T1D). In T1D, autoimmune attacks occur on pancreatic beta cells that secrete insulin, thereby compromising insulin level and glycemic control. Over time there is progressive deterioration of self-insulin secretion, poor capability to control glucose levels, and eventually, full external insulin dependence.
KMDA: 4.15 (+0.15)
